Plague – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Plague, a severe bacterial infection caused by the Gram-negative microorganism Yersinia pestis, exhibits two primary clinical forms: bubonic plague, marked by painful inflammation of lymph nodes referred to as “buboes,” accompanied by elevated body temperature and altered health condition, and pulmonary plague, which presents as chest discomfort, a cough producing bloody phlegm, heightened body temperature, changes in clinical state, and disturbances in consciousness. Plague transmission from animals to humans is facilitated by fleas, with rodents acting as the disease reservoir. Additionally, human-to-human transmission occurs through respiratory pathways. Diagnosis hinges on isolating the bacterium from buboes, blood, or respiratory secretions or through serological testing. Multiple classes of antibiotics have proven effective in combating Yersinia pestis, including aminoglycosides, tetracyclines, cotrimoxazole, rifampicin, fluoroquinolones, and others. Left untreated, the disease follows a swiftly fatal course.

Thelansis’s “Plague Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Plague treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Plague across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Plague Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Plague – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033